TransworldHealth

Lots of exciting developments at #ESMO26! Several important studies were also published simultaneously in major medical journals. A few highlights: 1. Small-cell lung cancer (NEJM): Adding tarlatamab to first-line durvalumab maintenance improved median overall survival from 12.7 to 21.1 months in the phase 3 DeLLphi-305 trial. 2. HER2-positive breast cancer (NEJM): Anbenitamab, a HER2-targeted bispecific antibody, plus HB1801 improved 24-month progression-free survival to 58.5% vs 34.4% with standard therapy (HR 0.46). 3. Muscle-invasive bladder cancer (NEJM): Perioperative durvalumab plus neoadjuvant enfortumab vedotin improved 24-month event-free survival to 63.5% vs 45.1% with surgery alone. 4. HR-positive, HER2-negative breast cancer (Lancet): The EGFR/HER3-targeted bispecific antibody-drug conjugate izalontamab brengitecan doubled median progression-free survival versus chemotherapy (8.2 vs 4.0 months; HR 0.41) in the phase 3 PANKU-Breast01 trial. 5. Melanoma (Nature Medicine): Five-year RELATIVITY-047 results showed sustained overall survival benefit with nivolumab + relatlimab vs nivolumab alone (HR 0.78). Full publications below 👇